This report describes a fatal case of the propofol infusion syndrome in an adult patient being sedated for a closed head injury using high doses of propofol. The features of circulatory collapse, metabolic acidosis, mild rhabdomyolysis and renal impairment are consistent with the syndrome and not readily attributable to alternative aetiologies. Potential mechanisms for the syndrome may relate to antagonism of beta-receptors, impaired myocardial oxygen utilization and a specific disruption to fatty-acid oxidation. This is the first published Australian case of the propofol infusion syndrome in an adult and should serve as an additional case report to the existing literature highlighting this potentially fatal syndrome in adults.
The propofol infusion syndrome has been progressively recognized as the association of unexplained myocardial failure, metabolic acidosis and rhabdomyolysis developing in the context of high-dose propofol treatment, sometimes associated with hyperkalaemia and renal failure. It is well recognized in children and more recently, a series of retrospective reviews and case reports have associated the syndrome with deaths in adults. We describe a fatal outcome in an adult patient in whom these features were present after receiving high-dose propofol for sedation required for the management of his closed head injury.
CASE REPORT
A 31-year old man was the driver of a vehicle that collided with a lamppost in which he sustained a closed head injury. He was noted to be having a seizure at the scene but it was unknown if this had preceded the accident. His past history included a single seizure three years previously attributed to cannabis use and for which a CT brain and EEG undertaken at that time were unremarkable.
On arrival at hospital, he was agitated, his vital signs were stable and further assessment did not reveal any injuries other than a closed head injury. He was intubated and sedated as part of his initial management. A CT scan of his brain was reported as normal and he was subsequently transferred to an Intensive Care Unit for further management. The initial ECG demonstrated an incomplete right bundle branch block and a QT interval within normal limits. A repeat ECG that day demonstrated similar changes with some peaking of the anterior T-waves.
A repeat CT brain scan on day 2 was reported as normal. On day 3, a lumbar puncture was performed because of his persistent agitation on weaning from sedation and to exclude the possibility of encephalitis, given the seizure evident at the time of the accident. This demonstrated increased CSF pressure (25 cm H 2 O) and an increased protein level, although subsequent culture was reportedly not positive for infection. An ECG showed lateral T-wave inversion and a troponin level taken at that time was recorded as being normal. Serial chest X-rays did not demonstrate any features of mediastinal or aortic injury.
Subsequent ECG changes were noted over the ensuing days. On day 4, a creatine kinase (CK) level was measured at 753 IU/l and similar lateral T wave inversion was identified. These ECG changes persisted into the next day (CK 11,044 IU/l), on that occasion being associated with inferior flattening and some prolongation of the QT interval. The CK remained elevated around 11,000 IU/l on day 6 and 7. A cardiology opinion suggested that these changes were most probably attributable to either raised intracranial pressure or myocarditis and acyclovir was commenced. His serum potassium concentrations over this time remained within normal limits.
Propofol was administered as the predominant sedative agent, combined on a number of days with intravenous morphine and midazolam. The propofol was administered as both a high-dose background intravenous infusion supplemented by intravenous bolus over the majority of the patient's admission (Table 1) .
On day 6, a third cranial CT scan was performed, which demonstrated features consistent with sinusitis. Around this time, the patient was noted to be tachycardic and his renal function had deteriorated from an initial normal creatinine level to 0.37 mmol/l, attributed to contrast nephropathy. Further, slurred elevation of the ST-T wave segments on the ECG was evident, which later that day developed into inferolateral ST segment elevation with reciprocal anterior changes. A transthoracic echocardiography examination demonstrated normal left ventricular size associated with moderate hypertrophy and preserved left ventricular function. It was further noted that the urine developed a green discolouration.
On day 8, the patient's clinical condition had deteriorated further and he was noted to have developed a metabolic acidosis (base excess -4.9 mmol/l, serum lactate 0.6 mmol/l). Further, the plasma was noted to be lipaemic and the propofol infusion was accordingly decreased. The ECG had progressively become more abnormal with bizarre ST-T wave changes and broadening of the QRS complex, giving the appearance of a near "sinusoidal" rhythm ( Figure 1 ). His cardiac rhythm degenerated into a polymorphic ventricular tachycardia and subsequent ventricular fibrillation for which resuscitation was unsuccessful. An autopsy failed to reveal any specific pathology to explain the circulatory collapse, rhabdomyolysis or renal impairment, and in particular there was no evidence of an undetected myocardial or aortic injury.
Based on the drug administration records, a total dose of 48 g was administered over the total admission duration of 157 hours. For the patient weight recorded as 75 kg, this equates to an average dose of 68 µg/kg/min (4.1 mg/kg/h). The maximum infusion rate recorded was 114 µg/kg/min (6.8 mg/kg/h). Over the 48 hours (day 6 and 7) prior to the patient's death, a total dose of 21g was administered at an average infusion dose of 97 µg/kg/min (5.8 mg/kg/h).
DISCUSSION
The recommended dose range for propofol varies according to its indication for use. For sedation in ventilated patients, a dose range of 1 to 3 mg/kg/h by infusion is recommended to achieve satisfactory sedation, whereas for maintenance of general anaesthesia a dose range of 4 to 12 mg/kg/h may be required 1 . According to this prescribing information, infusion of propofol is not recommended for sedation in children, based on reports of serious adverse events 2,3 , including fatalities that occurred at dose ranges in excess of 4 mg/kg/h and commonly as high as 10 mg/kg/h. The presence of lipaemia and an evolving acidosis are commented upon as being associated with subsequent fatal outcomes.
Guidelines published by the Society of Critical Care Medicine in alliance with the American College of Chest Physicians warn that prolonged use (>48 hours) of high doses of propofol (>66 µg/kg/min) may be associated with lactic acidosis, bradycardia and lipaemia in children and infusions of >83 µg/kg/ min have been associated with increased risk of cardiac arrest in adults 4 .
The propofol infusion syndrome has been defined as the association of unexplained myocardial failure, metabolic acidosis and rhabdomyolysis developing in the context of high-dose propofol treatment, sometimes associated with hyperkalaemia and renal failure 5 . The syndrome has been described in both the paediatric and adult literature in a series of case reports and retrospective reviews. Whilst many similar features are shared between these reports, the relationship between the syndrome and high-dose propofol has been regarded as an association only and no causal link has been clearly established. The largest adult retrospective series describes seven neurosurgical patients from a single centre who developed features consistent with the propofol infusion syndrome 6 . In that report, an odds ratio for developing the syndrome was 1.93 (95% CI 1.12-3.32) for every mg/kg/h increase in mean propofol dose above 5 mg/kg/h. Of the 67 patients from whom the seven were identified, 3 of 18 (17%) were receiving 5 to 6 mg/kg/h, 4 of 13 (31%) were receiving doses above 6 mg/kg/h, and all seven patients received the infusion for more than 58 hours. Four of the seven patients developed ventricular tachycardia, six had a metabolic acidosis, and the mean individual propofol dose ranged between 5.7 and 7.4 mg/kg/h. The onset of the syndrome ranged between 35 and 93 hours and death occurred 65 to 177 hours after commencement of the infusion. Single case reports describe many similar features to this series, commonly in head injured patients. The association with this clinical group presumably relates to the clinical requirement for high-level and prolonged sedation for control of intracranial hypertension rather than a particular clinical characteristic of the head injury per se. In one such report, an 18-year-old man died in circumstances attributable to the syndrome after sustaining multiple trauma in a motor vehicle accident. He received a propofol infusion of 5.8 mg/kg/h for 39 hours and later 7.6 mg/kg/h for a further 59 hours for sedation and died, after having lipaemic serum noted, from cardiovascular collapse associated with a metabolic acidosis and increased creatine kinase levels (20,520 IU/l) 7 . An ultimately fatal outcome also occurred in another head injured patient who received 126 µg/kg/min for 55 hours 4 . Similarly, a 21-year-old female in whom a cerebral arteriovenous malformation was embolized developed a reversible metabolic acidosis and haemodynamic instability associated with a high dose infusion of propofol used for post-procedure sedation 8 . She received a dose ranging from 75 to 150 µg/kg/min (approximately 4.5-9 mg/kg/h) for up to four days, and a total dose of 30,000 mg within a 48-hour period.
Potential mechanisms for this syndrome may relate to propofol's cardiac depressant effects 9 . The drug acts in a dose-dependent competitive manner to antagonize beta-receptors in rat myocardial membranes 10 . In an isolated perfused heart model in guinea pigs, propofol impaired oxygen utilization in the cardiomyocyte and further significantly depressed ventricular performance as measured by maximal dP/dt per cardiac cycle. These effects correlated linearly with the propofol infusion concentration 11 . Further, a specific disruption to fatty-acid oxidation caused by impaired entry of long-chain acylcarnitine esters into the mitochondria resulting in failure of the mitochondrial respiratory chain has been postulated 12 .
On the basis of measurements of the parent drug and metabolites, it has been noted that in two of the patients in whom death resulted, fourfold increases in levels of the parent compound 2,6 di-isopropylphenol were noted, whereas the metabolites were in the normal range 13 . These elevated levels may indirectly create a large lipid pool in the serum that acts as a reservoir for the 2,6 di-isopropylphenol and precludes its clinical action by preventing it reaching its site of action, despite increases in the infusion rate.
The features apparent in our patient prior to his death are consistent with the propofol infusion syndrome described above. The patient received high doses of propofol, over the entire admission, averaging 68 µg/kg/min (4.1 mg/kg/h), but over the 48 hours prior to his death, a total dose of 21,000 mg was administered at an average infusion dose of 97 µg/kg/min (5.8 mg/kg/h). These dosages are consistent with the dosages used in patients in whom the clinical features of the syndrome eventuated.
The consistent clinical features with the propofol infusion syndrome in this man included cardiovascular collapse, metabolic acidosis, rhabdomyolysis and renal impairment not explained by alternative aetiologies. The presence of green urine and lipaemic serum were further indicative of accumulation of propofol.
Consistent with previously described reports of this syndrome, high dosage propofol in this patient appears to be associated with a fatal outcome. However, on the basis of the available literature, a causal link is not clearly established. Clinicians should be aware of this syndrome in adults and a suggested maximum infusion rate of 3 mg/kg/h for sedation in adult patients is recommended.
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